RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
RhoVac publishes research results prior ASCO's meeting
Nyemission i RhoVac AB på Spotlight - Aktier
Market Notice 23/22 – Information regarding the rights issue from Rhovac AB
RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac appoints Professor Georg Holländer to its Scientific Advisory Board
Market notice 94/22 – RhoVac AB´s financial instruments are moved to the Observation List
RhoVac retains international investment bank as advisor for desired RV001 transaction
RhoVac's events during May - August
The Canadian Intellectual Property Office intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine
Share Information | Chosa Oncology
RhoVac aktie (RHOVAC) | Alla nyheter, analys, riktkurs… - Börskollen
First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom
Sweden's RhoVac Aims To Become An M&A Target :: Scrip
Another clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer
139/19 – Information regarding the rights issue from RhoVac AB
RhoVac AB will be transferred to Spotlight Stock Market's observation list
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac — Good execution in challenging times for industry - Edison Group
Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer
RhoVac's reports positive results from the 12 months follow-up of the company's phase I/II clinical study
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
RhoVac AB | Aktiespararna
RhoVac Confirms Forecast – BRaVac Phase IIb study recruitment to close in Quarter 3 2021
